The Corporate Reputation of Pharma in 2022 - The Patient Perspective - Neurology Edition: The Views of 258 Neurology Patient Groups

The ‘Corporate Reputation of Pharma’ survey - Neurology edition, is now in its 9th year. Between November 2021-February 2022, the survey collected the opinions of 258 neurology patient groups on the performance of the pharmaceutical industry during 2021.

Patient groups - and neurology patient groups especially - possess a deep and unique understanding of the patients they represent, and express the collated views of these patients. Patient-group perspectives have become increasingly important to regulators that demand patient input into trial design and conduct (as well as into the evaluation of clinical outcomes). At the same time, many patient groups are also familiar with the complexities of the pharmaceutical industry’s business. From their vantage point, therefore, patient groups are both able to assess pharma, and to recommend ways in which companies can improve - all from a patient perspective.

The report provides details on:

• How the analyst measures pharma’s corporate reputation from a patient perspective; 
• The companies included in the 2021 neurology analyses; 
• The headline results of the 2021 survey, from the perspective of neurology patient groups; and 
• The profiles of 2021’s respondent neurology patient groups. 

 The 20 companies included in the neurology arm of the 2021 ‘Corporate Reputation of Pharma’ analyses:  AbbVie - AstraZeneca - Bayer - Biogen - Boehringer Ingelheim - Bristol Myers Squibb - Eisai - Eli Lilly - Grünenthal - GSK - Janssen - Lundbeck - Merck KGaA/EMD Serono - Novartis - Pfizer - Roche/Genentech/Chugai - Sanofi - Takeda - Teva - UCB 

COMPANY RANKINGS IN THE FIELD OF NEUROLOGICAL CONDITIONS, 2021 

• The top-three pharma companies out of 20 companies, ranked for their overall corporate reputation in 2021, as assessed by respondent neurology patient groups familiar with the company: Roche, 1st - Novartis, 2nd - Biogen, 3rd. 
• The top-three pharma companies out of 12 companies, ranked for their overall corporate reputation in 2021, as assessed by respondent neurology patient groups working with the company: Roche, 1st - Novartis, 2nd - Pfizer, 3rd.   
• The top-three ‘big-pharma’ companies out of 11 companies, ranked for their overall corporate reputation in 2021, assessed by respondent neurology patient groups familiar with the company: Roche, 1st - Novartis, 2nd - Pfizer, 3rd. 
• The top-three ‘big-pharma’ pharma companies out of 6 companies, ranked for their overall corporate reputation in 2021, assessed by respondent neurology patient groups working with the company: Roche, 1st - Novartis, 2nd - Pfizer, 3rd.